Asset Details
Do you wish to reserve the book?
Safety Evaluation of Hemoglobin-Albumin Cluster “HemoAct” as a Red Blood Cell Substitute
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Safety Evaluation of Hemoglobin-Albumin Cluster “HemoAct” as a Red Blood Cell Substitute
Do you wish to request the book?
Safety Evaluation of Hemoglobin-Albumin Cluster “HemoAct” as a Red Blood Cell Substitute
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Safety Evaluation of Hemoglobin-Albumin Cluster “HemoAct” as a Red Blood Cell Substitute
2015
Overview
A hemoglobin (Hb) wrapped covalently by human serum albumins (HSAs), a core–shell structured hemoglobin-albumin cluster designated as “HemoAct”, is an O
2
-carrier designed for use as a red blood cell (RBC) substitute. This report describes the blood compatibility, hemodynamic response and pharmacokinetic properties of HemoAct and then explains its preclinical safety. Viscosity and blood cell counting measurements revealed that HemoAct has good compatibility with whole blood. Intravenous administration of HemoAct into anesthetized rats elicited no unfavorable increase in systemic blood pressure by vasoconstriction. The half-life of
125
I-labeled HemoAct in circulating blood is markedly longer than that of HSA. Serum biochemical tests conducted 7 days after HemoAct infusion yielded equivalent values to those observed in the control group with HSA. Histopathologic inspections of the vital organs revealed no marked abnormality in their tissues. All results indicate that HemoAct has sufficient preclinical safety as an alternative material for RBC transfusion.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 82
/ Albumin
/ Animals
/ Blood
/ Blood Substitutes - administration & dosage
/ Blood Substitutes - chemistry
/ Blood Substitutes - pharmacokinetics
/ Erythrocyte Transfusion - methods
/ Hemoglobins - administration & dosage
/ Hemoglobins - pharmacokinetics
/ Humanities and Social Sciences
/ Humans
/ Male
/ Rodents
/ Safety
/ Science
/ Serum Albumin - administration & dosage
